- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07581275
Plasma Kinetics of Levobupivacaine After Transversus Abdominis Plane (TAP) Block in Abdominal Surgery (LEVO-TAP-PK)
Plasma Kinetics of Levobupivacaine After Transversus Abdominis Plane (TAP) Block in Abdominal Surgery: A Prospective Study and Definition of a Safety Window for Intravenous Lidocaine Administration
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This prospective single-center pharmacokinetic observational study is designed to characterize systemic exposure to levobupivacaine after ultrasound-guided transversus abdominis plane (TAP) block performed as part of routine perioperative analgesia for elective abdominal surgery under general anesthesia.
TAP block is widely integrated into multimodal analgesic pathways because it may reduce postoperative pain and opioid requirements. However, administration of relatively large volumes of local anesthetic into fascial planes can result in measurable systemic absorption. Although levobupivacaine has a favorable safety profile compared with racemic bupivacaine, understanding peak plasma concentrations and their timing remains clinically relevant, particularly when additional analgesic strategies such as intravenous lidocaine may be considered during the perioperative period.
Eligible adult participants scheduled for abdominal surgery and already planned to receive TAP block according to institutional practice will be enrolled after informed consent. No changes to standard anesthetic or surgical management are mandated by the study. The TAP block will be performed by experienced anesthesiologists using the institutional standard technique with levobupivacaine 0.375% (total volume 40 mL; maximum dose 150 mg).
The reference time (T0) will be defined as completion of local anesthetic injection. Serial blood samples will be obtained during the early postoperative period at predefined time points up to 180 minutes after T0 to capture the expected absorption phase and early elimination profile. Plasma levobupivacaine concentrations will be quantified using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay.
The primary pharmacokinetic parameters of interest are maximum observed plasma concentration (Cmax) and time to maximum concentration (Tmax). Secondary analyses will include concentration-time profiles, area under the curve from 0 to 180 minutes (AUC0-180), interindividual variability, and exploratory evaluation of associations between exposure metrics and selected demographic or clinical variables such as age, body mass index, sex, and surgical category.
Results are expected to provide real-world pharmacokinetic data for levobupivacaine after TAP block and may help inform safer sequencing of multimodal analgesic approaches, including timing of intravenous lidocaine administration after fascial plane block. Safety monitoring will follow routine perioperative standards, and any suspected local anesthetic systemic toxicity will be managed immediately according to institutional protocols.
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Michele Carella, MD PhD
- Numéro de téléphone: +32 4 2843658
- E-mail: mcarella@chuliege.be
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Age ≥18 years
- Scheduled elective abdominal surgery under general anesthesia
- Planned ultrasound-guided TAP block as part of standard perioperative analgesic care
- Able to understand and speak French sufficiently to understand the study information and consent form
- Able and willing to provide written informed consent
Exclusion Criteria:
- Refusal or inability to provide informed consent
- Known allergy or hypersensitivity to amide local anesthetics
- Severe hepatic impairment
- Renal impairment (estimated glomerular filtration rate <50 mL/min/1.73 m²)
- Contraindication to repeated blood sampling or inability to complete the sampling schedule
- Participation in another clinical study that could affect absorption, distribution, metabolism, or elimination of local anesthetics
- Pregnancy
- Emergency surgery or life-threatening urgent condition
- Immediate postoperative instability requiring intensive care transfer (e.g., hemodynamic instability)
- Inability to understand French sufficiently for study information and consent
- Persons requiring special legal protection for consent (e.g., minors, guardianship, incapacity to consent)
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
TAP Block Pharmacokinetic Cohort
Adult participants undergoing elective abdominal surgery under general anesthesia at CHU Liège who receive an ultrasound-guided transversus abdominis plane (TAP) block with levobupivacaine 0.375% (total volume 40 mL; maximum dose 150 mg) as part of standard perioperative analgesic management.
This is a single observational cohort.
The intervention of interest is the routine TAP block, after which serial blood samples are collected up to 180 minutes to characterize plasma levobupivacaine pharmacokinetics.
No experimental treatment is assigned by the study.
|
Ultrasound-guided transversus abdominis plane (TAP) block performed as part of routine perioperative analgesia after induction of general anesthesia for elective abdominal surgery.
Levobupivacaine 0.375% is injected into the transversus abdominis fascial plane under real-time ultrasound visualization, using a total volume of 40 mL (typically bilateral administration, adjusted to surgical indication), with a maximum total dose of 150 mg.
The block is performed by an experienced anesthesiologist according to institutional standard practice.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Maximum Plasma Levobupivacaine Concentration (Cmax)
Délai: From completion of TAP block (T0) to 180 minutes post-block placement
|
Maximum observed plasma concentration (Cmax, µg/mL) of levobupivacaine after TAP block, determined from serial plasma samples collected during the first 180 minutes after completion of the block.
|
From completion of TAP block (T0) to 180 minutes post-block placement
|
|
Time to Maximum Plasma Levobupivacaine Concentration (Tmax)
Délai: From completion of TAP block (T0) to 180 minutes post-block placement
|
Time to maximum observed plasma concentration (Tmax, minutes) of levobupivacaine after TAP block, determined from serial plasma samples collected during the first 180 minutes after completion of the block.
|
From completion of TAP block (T0) to 180 minutes post-block placement
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Area Under the Plasma Concentration-Time Curve From 0 to 180 Minutes (AUC0-180) of Levobupivacaine
Délai: From completion of TAP block (T0) to 180 minutes post-block placement
|
Area under the plasma concentration-time curve (AUC0-180, µg·min/mL) of levobupivacaine following TAP block, calculated from serial plasma concentration measurements obtained during the first 180 minutes after completion of the block.
|
From completion of TAP block (T0) to 180 minutes post-block placement
|
|
Plasma Levobupivacaine Concentration at Each Sampling Time Point
Délai: From completion of TAP block (T0) to 180 minutes post-block placement.
|
Measured plasma concentration (µg/mL) of levobupivacaine at predefined sampling time points after TAP block.
|
From completion of TAP block (T0) to 180 minutes post-block placement.
|
|
Interindividual Variability of Maximum Plasma Levobupivacaine Concentration (Cmax)
Délai: From completion of TAP block (T0) to 180 minutes post-block placement
|
Interindividual variability of maximum plasma levobupivacaine concentration (Cmax), assessed using descriptive dispersion measures including standard deviation and coefficient of variation.
|
From completion of TAP block (T0) to 180 minutes post-block placement
|
|
Association Between Area Under the Plasma Concentration-Time Curve (AUC0-180) and Clinical Factors
Délai: From completion of TAP block (T0) to 180 minutes post-block placement
|
Association between levobupivacaine AUC0-180 (µg·min/mL) and predefined clinical factors including age, sex, body mass index (BMI), and type of surgery.
|
From completion of TAP block (T0) to 180 minutes post-block placement
|
|
Time to Reach Plasma Levobupivacaine Concentration Below Prespecified Safety Threshold
Délai: From completion of TAP block (T0) to 180 minutes post-block placement
|
Time required for plasma levobupivacaine concentrations to decrease below the predefined safety threshold considered compatible with initiation of intravenous lidocaine administration after TAP block.
|
From completion of TAP block (T0) to 180 minutes post-block placement
|
|
Interindividual Variability of Area Under the Plasma Concentration-Time Curve (AUC0-180)
Délai: From completion of TAP block (T0) to 180 minutes post-block placement
|
Interindividual variability of levobupivacaine AUC0-180, assessed using descriptive dispersion measures including standard deviation and coefficient of variation.
|
From completion of TAP block (T0) to 180 minutes post-block placement
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Vincent Bonhomme, MD PhD, Centre Hospitalier Universitaire de Liege
Publications et liens utiles
Publications générales
- Jokinen MJ, Neuvonen PJ, Lindgren L, Hockerstedt K, Sjovall J, Breuer O, Askemark Y, Ahonen J, Olkkola KT. Pharmacokinetics of ropivacaine in patients with chronic end-stage liver disease. Anesthesiology. 2007 Jan;106(1):43-55. doi: 10.1097/00000542-200701000-00011.
- Mann B, Burch E, Shakeshaft C. Attitudes Toward Acupuncture Among Pain Fellowship Directors. Pain Med. 2016 Mar;17(3):494-500. doi: 10.1093/pm/pnv001. Epub 2015 Dec 7.
- Atwill ER, Harp JA, Jones T, Jardon PW, Checel S, Zylstra M. Evaluation of periparturient dairy cows and contact surfaces as a reservoir of Cryptosporidium parvum for calfhood infection. Am J Vet Res. 1998 Sep;59(9):1116-21.
- Yun H, Park M, Lee H, Choi EK. Healthcare Interventions for Children Using Nonimmersive Virtual Reality: A Mixed Methods Systematic Review. J Pediatr Health Care. 2024 Sep-Oct;38(5):703-716. doi: 10.1016/j.pedhc.2024.01.008. Epub 2024 Mar 10.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- B7072026000035
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .